<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8089">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01716104</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-AZ-001</org_study_id>
    <nct_id>NCT01716104</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression</brief_title>
  <official_title>Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  To assess safety of Afalaza drug within 12 months in patients with symptoms of benign
           prostatic hyperplasia and risk of progression.

        -  To assess efficiency of Afalaza drug within 12 months in patients with symptoms of
           benign prostatic hyperplasia and risk of progression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in total IPSS scores (International Prostate Symptome Score) after 1, 3, 6 and 12 months compared to baseline.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dynamics of irritative symptoms evaluated by IPSS (International Prostate Symptome Score) after 1, 3, 6 and 12 months compared to baseline</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Afalaza (2 tablets twice a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (2 tablets twice a day)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afalaza</intervention_name>
    <description>Safety and Efficiency</description>
    <arm_group_label>Afalaza (2 tablets twice a day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Safety and Efficiency</description>
    <arm_group_label>Placebo (2 tablets twice a day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male patients 45 to 60 y.o. inclusive with a documented diagnosis of Benign prostatic
             hyperplasia.

          2. Lower urinary tract symptoms having been experienced for 3 months and longer.

          3. Total IPSS score (International Prostate Symptome Score) of 8 to 15.

          4. Prostate volume of more than 30 cm3.

          5. Maximal urinary flow rate of 10-15 mL/sec.

          6. Micturition volume of 125-350 mL.

          7. Residual volume of less than 100 mL.

          8. Serum PSA level of less than 4 ng/mL.

          9. Use of and compliance with contraceptive methods during the trial and for 30 days
             upon completion of participation in the trial.

         10. Presence of the patient's information sheet (informed consent form) for participation
             in the clinical trial.

        Exclusion Criteria:

          1. Invasive therapies for BPH including a transurethral prostatic resection,
             thermotherapy, microwave therapy, transurethral needle ablation, stenting , etc.

          2. Malignant oncological disease of the urogenital system as well as malignancies of any
             other localization during last 5 years.

          3. Acute urinary retention within 3 months before inclusion in the trial.

          4. Neurogenic dysfunctions and bladder ears.

          5. Urinary stone disease.

          6. Urethral stricture, bladder neck sclerosis.

          7. History of operative aids for pelvic organs.

          8. Urogenital infections in the phase of active inflammation.

          9. Systematic administration of agents exhibiting effects on bladder function and urine
             production.

         10. Exacerbation or decompensation of chronic diseases affecting the possibility of
             patients to participate in the clinical trial, including severe concurrent
             cardiovascular conditions and disorders of the nervous system, renal and hepatic
             insufficiency.

         11. History of administration of testosterone 5-alpha-reductase inhibitors (finasteride,
             dutasteride).

         12. History of polyvalent allergy.

         13. Allergy/intolerance to any component of drug agents used in the therapy.

         14. Malabsorption syndrome, including congenital or acquired lactase or other
             disaccharidase deficiency.

         15. Administration of drugs specified as &quot;Prohibited concomitant therapy&quot;, within 3
             months before enrollment.

         16. Exacerbation or decompensation of chronic diseases affecting the possibility of
             patients to participate in the clinical trial.

         17. Drug and alcohol consumption (over 2 alc. units daily), mental diseases. Legal
             incapacity or limited legal capacity.

         18. Legal incapacitation or limited legal capacity.

         19. Patients, who, in the investigator's opinion, will fail to observe the requirements
             during the trial or adhere to the studied drug administration procedure.

         20. Participation in other clinical trials within 3 months before enrolment in this
             trial.

         21. Presence of other factors, complicating the patient's participation in the trial
             (e.g., planned lengthy business and other trips).

         22. A patient is a part of the center's research staff, taking a direct part in the
             trial, or an immediate family member of the investigator. Immediate family members
             are defined as spouses, parents, children or siblings, regardless of whether full
             blood or adopted.

         23. The patient is employed with Scientific Production Firm Materia Medica Holding LLC,
             i.e. is the company's employee, part-time employee under contract, or appointed
             official in charge of the trial, or their immediate family.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD</last_name>
    <phone>+74957836804</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>The State Budget Educational institution of High Professional Training I.M. Sechenov First Moscow State Medical University of Ministry of Health Care and Social Development of the Russian Federation, Department of Urology</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Vinarov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Andrey Vinarov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Federal State Budget Educational institution of High Professional Training &quot;Peoples' Friendship University of Russia&quot;, Department of Urology and Operative Nephrology</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Avdoshin, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Vladimir Avdoshin, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Care institution of Moscow the City &quot;Hospital for veterans of wars No. 2 of the Administration of Health Care of Moscow City&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>109472</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Kornev, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexey Kornev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Care institution of Moscow the City &quot;Specialized clinical (neuro-psychiatric) hospital No. 8 n.a. Z.P. Solovyov - ''Clinic of neuroses&quot; of the Administration of Health Care of Moscow City</name>
      <address>
        <city>Moscow</city>
        <zip>115419</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Korshunova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ekaterina Korshunova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Federal State Budget institution &quot;Polyclinic № 3&quot; of Affairs Management Department of the President of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vadim Surikov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vadim Surikov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Treatment-and-Prophylactic Health Care institution Clinical Diagnostic Centre &quot;Zdorovie&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Aboyan, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Igor Aboyan, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Hospital OrCli&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Heifetz, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Vladimir Heifetz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Federal State institution &quot;All-Russian center of emergency and radiation medicine n.a. A.M. Nikiforov&quot; of the Ministry of the Russian Federation for Affairs of civil defence, emergencies and elimination of consequences of natural disasters</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Petrov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Sergey Petrov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budget Health Care institution &quot;Pokrovsky city hospital&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Gorelov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Andrey Gorelov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 23, 2013</lastchanged_date>
  <firstreceived_date>October 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
